|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||49.36 - 50.53|
|52-week range||49.36 - 50.53|
|Beta (5Y monthly)||1.36|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
If you want to know who really controls FibroGen, Inc. ( NASDAQ:FGEN ), then you'll have to look at the makeup of its...
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...
On Monday, investors pushed down its stock price by 9%. The company announced that the Food and Drug Administration's (FDA) review of the company's new drug application (NDA) for roxadustat has been extended by three months. As the original action date was today, investors are coping with the one-two disappointment of FibroGen's failure to get a regulatory present in time for the holidays, and of roxadustat's inability to barrel into the new year as a marketable drug.